SRPT
Sarepta Therapeutics, Inc.
Healthcare · Biotechnology
Deeply Undervalued·Quality 60·RSI 66·DCF -5772%·Conviction 75
Investment Thesis — Sarepta Therapeutics, Inc.
The market is pricing Sarepta as if its pipeline is effectively dead and future cash flows are highly uncertain, ignoring the embedded optionality in its gene therapy platform. This extreme pessimism overlooks the potential for regulatory or clinical inflection points that could rapidly re-rate the stock.
Catalysts
- Upcoming regulatory decisions on lead gene therapy candidates
- Interim clinical trial data readouts
- Potential strategic partnership or acquisition interest
Risk Factors
- Negative clinical trial outcomes
- Regulatory rejection or delays
- Accelerated cash burn leading to dilutive financing
Key Debates
Exon-skipping revenue rebound to 5% growth by H2 2024
SRPT's 6.59x P/E expands to 15x by Q3 on Elevidys
SRPT recovers to 21.57 Analyst PT by H2 2024